JP7026507B2 - 眼において薬物徐放を達成する方法及び生体適合性組成物 - Google Patents

眼において薬物徐放を達成する方法及び生体適合性組成物 Download PDF

Info

Publication number
JP7026507B2
JP7026507B2 JP2017504772A JP2017504772A JP7026507B2 JP 7026507 B2 JP7026507 B2 JP 7026507B2 JP 2017504772 A JP2017504772 A JP 2017504772A JP 2017504772 A JP2017504772 A JP 2017504772A JP 7026507 B2 JP7026507 B2 JP 7026507B2
Authority
JP
Japan
Prior art keywords
drug
wafer
eye
nanomesh
wafer according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017504772A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017526655A5 (enExample
JP2017526655A (ja
Inventor
シーカ ピー． バルマン
モリー リュウ
コーシック バルマン
ケビン エル． ワード
ブレンダン ハケット
Original Assignee
インテグラル バイオシステムズ エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by インテグラル バイオシステムズ エルエルシー filed Critical インテグラル バイオシステムズ エルエルシー
Publication of JP2017526655A publication Critical patent/JP2017526655A/ja
Publication of JP2017526655A5 publication Critical patent/JP2017526655A5/ja
Priority to JP2021160573A priority Critical patent/JP2022001582A/ja
Application granted granted Critical
Publication of JP7026507B2 publication Critical patent/JP7026507B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007—Drug-containing films, membranes or sheets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/0008—Introducing ophthalmic products into the ocular cavity or retaining products therein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
    • A61M31/002—Devices for releasing a drug at a continuous and controlled rate for a prolonged period of time
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/0008—Introducing ophthalmic products into the ocular cavity or retaining products therein
    • A61F9/0017—Introducing ophthalmic products into the ocular cavity or retaining products therein implantable in, or in contact with, the eye, e.g. ocular inserts

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Anesthesiology (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Materials For Medical Uses (AREA)
JP2017504772A 2014-09-06 2015-09-08 眼において薬物徐放を達成する方法及び生体適合性組成物 Active JP7026507B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021160573A JP2022001582A (ja) 2014-09-06 2021-09-30 眼において薬物徐放を達成する方法及び生体適合性組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462046918P 2014-09-06 2014-09-06
US62/046,918 2014-09-06
PCT/US2015/048795 WO2016037169A1 (en) 2014-09-06 2015-09-08 Methods and biocompatible compositions to achieve sustained drug release in the eye

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021160573A Division JP2022001582A (ja) 2014-09-06 2021-09-30 眼において薬物徐放を達成する方法及び生体適合性組成物

Publications (3)

Publication Number Publication Date
JP2017526655A JP2017526655A (ja) 2017-09-14
JP2017526655A5 JP2017526655A5 (enExample) 2018-08-30
JP7026507B2 true JP7026507B2 (ja) 2022-02-28

Family

ID=55440434

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017504772A Active JP7026507B2 (ja) 2014-09-06 2015-09-08 眼において薬物徐放を達成する方法及び生体適合性組成物
JP2021160573A Withdrawn JP2022001582A (ja) 2014-09-06 2021-09-30 眼において薬物徐放を達成する方法及び生体適合性組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021160573A Withdrawn JP2022001582A (ja) 2014-09-06 2021-09-30 眼において薬物徐放を達成する方法及び生体適合性組成物

Country Status (12)

Country Link
US (2) US9931306B2 (enExample)
EP (1) EP3188688B1 (enExample)
JP (2) JP7026507B2 (enExample)
KR (1) KR102456032B1 (enExample)
CN (2) CN106604695B (enExample)
AU (2) AU2015311637B2 (enExample)
CA (1) CA2960213C (enExample)
ES (1) ES2900025T3 (enExample)
MY (1) MY178327A (enExample)
SG (1) SG11201701714RA (enExample)
WO (1) WO2016037169A1 (enExample)
ZA (2) ZA201701467B (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9931306B2 (en) * 2014-09-06 2018-04-03 Integral Biosystems Llc Methods and biocompatible compositions to achieve sustained drug release in the eye
WO2017062770A1 (en) * 2015-10-08 2017-04-13 Silverberg Noah Punctal plug and bioadhesives
CA3038115A1 (en) * 2016-09-30 2018-04-05 Mati Therapeutics Inc. Ophthalmic drug sustained release formulation and uses thereof
WO2018067882A1 (en) 2016-10-05 2018-04-12 Titan Pharmaceuticals, Inc. Implantable devices for drug delivery with reduced burst release
EP3630024B1 (en) * 2017-05-22 2022-04-06 California Institute of Technology Small molecule transport device with anti-condensation filler for drug delivery or waste removal
JP2020527591A (ja) * 2017-07-17 2020-09-10 ウルフクリーク バイオテック プライベート リミテッド 活性薬剤送達のための微粒子製剤
JP7373207B2 (ja) 2018-03-01 2023-11-02 バー‐イラン、ユニバーシティー 眼の状態の矯正に使用するためのシステム、方法、及び材料組成物
MA52774A (fr) * 2018-06-05 2021-04-14 Corneat Vision Ltd Timbre de greffe ophtalmique synthétique
CN109853054A (zh) * 2019-02-27 2019-06-07 上海交通大学医学院附属第九人民医院 一种同轴静电纺丝三维打印生物支架的装置及搭建方法
EP3701974B1 (en) * 2019-02-28 2024-08-28 Agency for Science, Technology and Research A material suitable for use as a vitreous substitute and related methods
CA3132635A1 (en) * 2019-03-05 2020-09-10 Aerie Pharmaceuticals, Inc. Pharmaceutical compositions for treating ocular diseases or disorders
WO2020198798A1 (en) * 2019-04-02 2020-10-08 Cytomatrix Limited A composition for the delivery of biologically active agents and uses thereof
TWI826685B (zh) 2019-05-02 2023-12-21 瑞士商愛爾康公司 可溶解聚合物眼睛插入物及其使用方法
CA3149866A1 (en) 2019-10-24 2021-04-29 Denis E. Labombard Ocular device and drug delivery system, with case
BR112022011067A2 (pt) * 2019-12-10 2022-08-23 Alcon Inc Insertos oculares poliméricos dissolvíveis com um polímero biodegradável
EP4142664A4 (en) * 2020-04-27 2024-05-29 Ocular Therapeutix, Inc. METHODS FOR TREATING ALLERGIC CONJUNCTIVITIS
KR102467288B1 (ko) * 2020-06-09 2022-11-17 동국대학교 산학협력단 결막 접촉용 약물 전달기
EP3928805A1 (en) * 2020-06-26 2021-12-29 Royal College of Surgeons in Ireland A device for use in the delivery of an active agent
US20220160668A1 (en) * 2020-11-23 2022-05-26 Sight Sciences, Inc. Formulations and methods for treating conditions of the eye
WO2022250977A1 (en) * 2021-05-26 2022-12-01 The Texas A&M University System Biodegradable mucoadhesive pharmaceutical formulations and methods thereof
CN114869862A (zh) * 2022-04-24 2022-08-09 温州医科大学附属眼视光医院 一种带引流功能的青光眼手术缓释抗瘢痕膜及制备方法
AU2024330194A1 (en) * 2023-08-31 2026-04-02 University Of Tennessee Research Foundation Sustained release ocular implants
TW202547517A (zh) * 2024-06-06 2025-12-16 美商視爾普斯眼科公司 用於治療眼部疾病之組合物及方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090269391A1 (en) 2008-04-29 2009-10-29 Ocugenics, L.L.C. Drug Delivery System And Methods Of Use
US20090269392A1 (en) 2008-04-29 2009-10-29 Ocugenics, LLC Drug Delivery System And Methods Of Use
JP2013511527A (ja) 2009-11-17 2013-04-04 アーセナル メディカル， インコーポレイテッド 薬物添加繊維

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5026559A (en) * 1989-04-03 1991-06-25 Kinaform Technology, Inc. Sustained-release pharmaceutical preparation
US5177168A (en) * 1989-10-17 1993-01-05 Polymer Technology Corp. Polymeric compositions useful in oxygen permeable contact lenses
JPH10509696A (ja) 1994-10-12 1998-09-22 フォーカル， インコーポレイテッド 生分解性ポリマーを介する標的化送達
US8273366B2 (en) 2002-06-05 2012-09-25 University Of Florida Research Foundation, Incorporated Ophthalmic drug delivery system
CA2601864A1 (en) * 2005-04-08 2006-10-19 Surmodics, Inc. Sustained release implants and methods for subretinal delivery of bioactive agents to treat or prevent retinal disease
CA2609687C (en) * 2005-05-24 2014-04-22 Inspire M.D Ltd. Stent apparatuses for treatment via body lumens and methods of use
AU2006348901C1 (en) * 2006-09-28 2013-11-14 Essity Hygiene And Health Aktiebolag Absorbent article, belt structure, manufacturing method for a belt structure and manufacturing method for an absorbent article
US8614103B2 (en) * 2006-10-27 2013-12-24 Lpath, Inc. Compositions and methods for treating sphingosine-1-phosphate (S1P) related ocular diseases and conditions
CA2670944A1 (en) * 2006-12-18 2008-06-26 Alcon Research, Ltd. Devices and methods for ophthalmic drug delivery
US8974814B2 (en) * 2007-11-12 2015-03-10 California Institute Of Technology Layered drug delivery polymer monofilament fibers
US20100104654A1 (en) * 2008-10-27 2010-04-29 Allergan, Inc. Prostaglandin and prostamide drug delivery systems and intraocular therapeutic uses thereof
JP5890182B2 (ja) 2009-02-12 2016-03-22 インセプト エルエルシー ヒドロゲルプラグによる薬物送達
US20100247606A1 (en) * 2009-03-25 2010-09-30 Allergan, Inc. Intraocular sustained release drug delivery systems and methods for treating ocular conditions
US8961600B2 (en) * 2009-06-25 2015-02-24 Optonol Ltd. Method of using a fiber matrix for maintaining space in soft tissues
KR102337046B1 (ko) 2010-01-22 2021-12-08 알러간, 인코포레이티드 전방내 서방성 치료제 이식물
US20110229551A1 (en) * 2010-03-17 2011-09-22 Notus Laboratories, Inc. Drug delivery compositions and methods using nanofiber webs
US9028860B2 (en) * 2010-04-28 2015-05-12 Poly-Med, Inc. Partially microcellular, selectively hydrophilic composite construct for ocular drug delivery
WO2012114138A1 (fr) * 2011-02-21 2012-08-30 Cerebel-Invest Sa Implants biodégradables pour la libération contrôlée sous-conjonctivale d'une molécule active
EP3494959A3 (en) 2011-04-29 2019-09-11 Allergan, Inc. Sustained release latanoprost implant
CA2848397C (en) 2011-09-14 2022-04-26 Forsight Vision5, Inc. Ocular insert apparatus and methods
CN203089455U (zh) * 2013-02-01 2013-07-31 浙江大学医学院附属第二医院 襻上镶嵌有药物缓释微囊的人工晶状体
US9931306B2 (en) * 2014-09-06 2018-04-03 Integral Biosystems Llc Methods and biocompatible compositions to achieve sustained drug release in the eye

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090269391A1 (en) 2008-04-29 2009-10-29 Ocugenics, L.L.C. Drug Delivery System And Methods Of Use
US20090269392A1 (en) 2008-04-29 2009-10-29 Ocugenics, LLC Drug Delivery System And Methods Of Use
JP2013511527A (ja) 2009-11-17 2013-04-04 アーセナル メディカル， インコーポレイテッド 薬物添加繊維

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Ｅｕｒｏｐｅａｎ Ｊｏｕｒｎａｌ ｏｆ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｓｃｉｅｎｃｅｓ，２０１４年 ３月，Ｖｏｌ．５３，ｐ１０－１６

Also Published As

Publication number Publication date
AU2019250153B2 (en) 2021-02-04
JP2022001582A (ja) 2022-01-06
CN106604695A (zh) 2017-04-26
MY178327A (en) 2020-10-08
EP3188688A1 (en) 2017-07-12
ES2900025T3 (es) 2022-03-15
SG11201701714RA (en) 2017-04-27
US20170296483A1 (en) 2017-10-19
KR102456032B1 (ko) 2022-10-18
US9931306B2 (en) 2018-04-03
US20180280313A1 (en) 2018-10-04
JP2017526655A (ja) 2017-09-14
AU2019250153A1 (en) 2019-10-31
EP3188688A4 (en) 2018-07-25
ZA201705792B (en) 2018-12-19
WO2016037169A1 (en) 2016-03-10
AU2015311637B2 (en) 2019-07-18
AU2015311637A1 (en) 2017-03-23
KR20170052582A (ko) 2017-05-12
CA2960213A1 (en) 2016-03-10
CN106604695B (zh) 2018-10-23
US10328033B2 (en) 2019-06-25
EP3188688B1 (en) 2021-11-03
CN109481447A (zh) 2019-03-19
CA2960213C (en) 2023-03-28
ZA201701467B (en) 2018-04-25
NZ729467A (en) 2024-04-26

Similar Documents

Publication Publication Date Title
AU2019250153B2 (en) Methods and biocompatible compositions to achieve sustained drug release in the eye
Allyn et al. Considerations for polymers used in ocular drug delivery
JP6751669B2 (ja) 眼科及び／又はその他の応用のための組成物及び方法
Chennamaneni et al. Development of a novel bioerodible dexamethasone implant for uveitis and postoperative cataract inflammation
CA2830555A1 (en) Intraocular drug delivery device and associated methods
Mandal et al. Developments in emerging topical drug delivery systems for ocular disorders
Prieto et al. Dexamethasone delivery to the ocular posterior segment by sustained-release Laponite formulation
Kaushal et al. Nanocarriers based ocular therapeutics: updates, challenges and future prospectives
Sahin et al. Spanlastics ocular delivery: a comprehensive review of formulation and therapeutic potential
Meshram et al. Ocular in Situ gels: Development, evaluation and advancements
US20200206137A1 (en) Microparticle formulations for delivery of active agents
Singh et al. Emphasis on Nanostructured Lipid Carriers in the Ocular Delivery of Antibiotics
Kaushik et al. Novel approaches in ocular drug delivery-A revolution
Jani et al. Ocular drug delivery systems
HK40003833A (zh) 用於在眼中实现持续药物释放的方法和生物相容性组合物
Bhaskar et al. Eye Drops to smart gels: The future of ocular drug delivery.
Herrero-Vanrell et al. Ocular pharmacokinetic drug, bioavailability and intraocular drug delivery systems
Pravin et al. Ocular Drug Delivery and Novel Formulations: A Review
HK1235660B (en) Methods and biocompatible compositions to achieve sustained drug release in the eye
Tawfik Dual Drug-Loaded Electrospun Nanofibres for the Treatment of Corneal Diseases
Bhanu Malhotra et al. Ocular drug delivery systems.
Schmitt Design and development of ocular formulations for preclinical and clinical trials
JP2015074641A (ja) 眼内薬物送達デバイスおよび付随する方法
Capítulo Nanoparticles as Ocular Drug Delivery Systems
AU2019204106A1 (en) Intraocular drug delivery device and associated methods

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170307

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180713

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180713

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20190221

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190312

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190610

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190809

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20190809

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200128

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200527

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20200527

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20200609

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20200616

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20200703

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20200707

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20201124

C13 Notice of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: C13

Effective date: 20210330

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20210413

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210603

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210726

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210824

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210930

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20211001

C23 Notice of termination of proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C23

Effective date: 20220104

C03 Trial/appeal decision taken

Free format text: JAPANESE INTERMEDIATE CODE: C03

Effective date: 20220208

C30A Notification sent

Free format text: JAPANESE INTERMEDIATE CODE: C3012

Effective date: 20220208

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220215

R150 Certificate of patent or registration of utility model

Ref document number: 7026507

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250